文献速递胸部肿瘤

FIR研究:阿替利珠单抗在PD-L1选定NSCLC中的疗效、安全性与生物标志物分析

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.
PubMed 文献 · J Thorac Oncol · 2018-01-01

FIR是一项II期开放标签研究,纳入138例PD-L1 TC2/3或IC2/3的晚期NSCLC患者,接受阿替利珠单抗1200 mg每21天一次。研究者评估的客观缓解率在化疗初治组、二线及以上无脑转移组、二线及以上有脑转移组分别为32%、21%、23%,安全性与此前试验一致。

要点

  • PD-L1 TC2/3或IC2/3晚期NSCLC中阿替利珠单抗单药有临床活性。
  • 伴脑转移患者也可观察到缓解,ORR为23%。
  • 88.6%配对样本TC/IC PD-L1表达变化<5%。

核心结论

  • 阿替利珠单抗单药在PD-L1选定晚期NSCLC中显示临床活性,包括伴脑转移患者,安全性与此前试验一致。

研究设计与样本

  • FIR为II期开放标签研究(NCT01846416),纳入PD-L1 TC2/3或IC2/3的晚期NSCLC患者138例。
  • 患者分三队列:化疗初治或辅助化疗后>6个月复发(31例)、二线及以上无脑转移(93例)、二线及以上伴已治疗脑转移(13例)。
  • 患者接受阿替利珠单抗1200 mg第1天给药,21天为一周期。
  • 主要终点为研究者评估的改良RECIST客观缓解率(RECIST v1.1)。

主要发现

  • 研究者评估的ORR在队列1、2、3分别为32%、21%、23%。
  • 治疗相关不良事件发生率在队列1、2、3分别为81%、67%、69%。
  • 3-4级治疗相关不良事件发生率在队列1、2、3分别为16%、19%、15%。
  • 88.6%(86/97)配对基线肿瘤样本的TC/IC PD-L1表达随时间变化<5%。

关键数值与推荐

  • PD-L1 TC2/3定义为≥5%肿瘤细胞PD-L1染色,IC2/3定义为≥5%肿瘤浸润免疫细胞PD-L1染色,采用SP142免疫组化法测定。

临床怎么用

  • 对于PD-L1 TC2/3或IC2/3的晚期NSCLC患者,阿替利珠单抗单药可作为治疗选择之一。
  • 伴已治疗脑转移的患者也可考虑使用阿替利珠单抗单药治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The FIR phase II study (NCT01846416) evaluated the efficacy and safety of anti-programmed death-ligand 1 (PD-L1) atezolizumab in advanced NSCLC selected by tumor cell (TC) or tumor-infiltrating immune cell (IC) PD-L1 expression. METHODS: Patients with PD-L1 TC2/3 (PD-L1 staining on ≥5% of TC) or IC2/3 tumors (PD-L1 staining on ≥5% of IC; determined by SP142 PD-L1 immunohistochemistry assay) with paired fresh and archival histology samples were recruited into cohort 1 (chemotherapy-naive/>6 months between adjuvant chemotherapy and recurrence), cohort 2 (≥ second-line without brain metastases), or cohort 3 (≥ second-line with treated brain metastases). Patients received 1200 mg atezolizumab on day 1 (21-day cycles). Primary endpoint was investigator-assessed modified Response Evaluation Criteria in Solid Tumors, objective response rate (Response Evaluation Criteria in Solid Tumors v1.1). Secondary endpoints were overall survival, progression-free survival, duration of response, and safety. RESULTS: Patients (N = 138) were enrolled (137 evaluable for response: cohort 1, n = 31; cohort 2, n = 93; and cohort 3, n = 13). Investigator-assessed objective response rate was 32%, 21%, and 23% for cohorts 1, 2, and 3, respectively. Treatment-related adverse events were reported in 81%, 67%, and 69% of patients, respectively, including grade 3-4 treatment-related adverse events in 16%, 19%, and 15%, respectively. Moreover, 88.6% (86 of 97) paired baseline tumor samples had <5% change in TC/IC PD-L1 expression over time. CONCLUSIONS: Atezolizumab monotherapy showed clinical activity in patients with NSCLC, including those with brain metastases; safety was consistent with previous trials. Atezolizumab has completed phase III monotherapy studies in second-line. Front-line trials are ongoing, confirming these favorable results.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Spigel DR, Chaft JE, Gettinger S, et al. FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC. J Thorac Oncol. 2018. PMID: 29775807. doi:10.1016/j.jtho.2018.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。